Enfuvirtide
FDA-approved injectable HIV fusion inhibitor (Fuzeon).
What it's for
Enfuvirtide is a 36–amino-acid peptide corresponding to a region of HIV-1 gp41. It is used with other antiretrovirals in treatment-experienced HIV-1 infection when appropriate.
What it does for the body
It is used with other antiretrovirals in treatment-experienced HIV-1 infection when appropriate. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
It binds gp41 and blocks the conformational change required for viral-host membrane fusion, preventing entry. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Enfuvirtide has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Immune research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Enfuvirtide — FDA.gov search
- ClinicalTrials.gov search: Enfuvirtide — U.S. clinical trials registry
- Drugs@FDA search: Enfuvirtide — FDA drug database (if approved)
- PubMed search: Enfuvirtide — NCBI PubMed
- PubMed Central search: Enfuvirtide — NCBI PMC